drugset / Trial / NCT05233956

Levonorgestrel Intrauterine System Effects on Hemoglobin and Serum Ferritin Among Anemic Women in Kenya

NCT05233956

RandomizedParallel-groupOpen-labelTreatment

Summary

Women with mild/moderate anemia who are seeking contraception will be randomized to a levonorgestrel (LNG) intrauterine system (IUS) or an LNG/ethinyl estradiol (EE)/ferrous fumarate combined oral contraceptive (COC) regimen and followed prospectively for 12-18 months. Approximately 400 participants will be enrolled. The primary hypothesis that the mean change in hemoglobin in the group assigned to the LNG IUS will be superior to the COC/ferrous fumarate (control) group after 12-months of product use.

Timeline

Start
2023-10-23
Primary completion
2026-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject COCs Unknown 0.15 mg Oral
Subject Ferrous Sulfate Diagnostic / imaging agent 75 mg Oral
Subject ethinyl estradiol Small molecule 30 ug Oral

Indications